newsfilter
← Latest News
PR Newswire·

Curis Announces Additional Data from TakeAim Leukemia Study

Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small...